183 related articles for article (PubMed ID: 19402870)
1. A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.
Haines I; Elliott P; Stanley R
Intern Med J; 2009 Apr; 39(4):269-71. PubMed ID: 19402870
[No Abstract] [Full Text] [Related]
2. Fludarabine for chronic lymphocytic leukemia.
Marchetti M; Barosi G; Liberato LN
N Engl J Med; 2001 Apr; 344(15):1166-7; author reply 1167-8. PubMed ID: 11302140
[No Abstract] [Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
4. Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
Nabhan C
Clin Cancer Res; 2008 Jul; 14(13):4353. PubMed ID: 18594019
[No Abstract] [Full Text] [Related]
5. Fludarabine: new indication. First-line treatment of CLL: unconvincing evidence.
Prescrire Int; 2005 Feb; 14(75):3-5. PubMed ID: 15747447
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.
Hyde C; Wake B; Bryan S; Barton P; Fry-Smith A; Davenport C; Song F
Health Technol Assess; 2002; 6(2):1-89. PubMed ID: 12022937
[No Abstract] [Full Text] [Related]
7. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
[TBL] [Abstract][Full Text] [Related]
8. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
10. In defence of the use of modern chemotherapy regimens for the treatment of patients with chronic lymphocytic leukaemia.
Tam CS
Intern Med J; 2009 Dec; 39(12):858-9. PubMed ID: 20233254
[No Abstract] [Full Text] [Related]
11. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
Ahmadi T; Schuster SJ
J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
[No Abstract] [Full Text] [Related]
12. Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.
MacCallum S; Groves M; Brass D; Cunningham J; Sales M; Gelly K; Tauro S
J Clin Pathol; 2009 May; 62(5):468-70. PubMed ID: 19398596
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.
Ayyildiz O; Isikdogan A; Bolaman Z; Muftuoglu E
Saudi Med J; 2004 Dec; 25(12):2054-6. PubMed ID: 15711709
[No Abstract] [Full Text] [Related]
14. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Catovsky D; Richards S; Matutes E; Oscier D; Dyer M; Bezares RF; Pettitt AR; Hamblin T; Milligan DW; Child JA; Hamilton MS; Dearden CE; Smith AG; Bosanquet AG; Davis Z; Brito-Babapulle V; Else M; Wade R; Hillmen P; ;
Lancet; 2007 Jul; 370(9583):230-239. PubMed ID: 17658394
[TBL] [Abstract][Full Text] [Related]
15. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
16. Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.
Molica S
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1333-40. PubMed ID: 21929307
[TBL] [Abstract][Full Text] [Related]
17. [Selective aplasia of the red-cell series after fludarabine administration in a patient with chronic B-cell lymphatic leukemia].
Antich Rojas J; Balaguer H; Cladera A
Sangre (Barc); 1997 Jun; 42(3):254-6. PubMed ID: 9381277
[No Abstract] [Full Text] [Related]
18. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
19. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszyńska A; Roliński J
Leuk Res; 2007 Mar; 31(3):411-2. PubMed ID: 16978694
[No Abstract] [Full Text] [Related]
20. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
Laurenti L; Piccioni P; Tarnani M; De Padua L; Garzia M; Efremov DG; Piccirillo N; Chiusolo P; Sica S; Leone G
Leuk Res; 2007 Feb; 31(2):253-6. PubMed ID: 16815546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]